a) Terbinafine Tablets USP 250mg Taj Pharma
b) Terbinafine Tablets USP 500mg Taj Pharma

a) Each tablet contains
Terbinafine USP 250mg
(as terbinafine hydrochloride)
Excipients     q.s.

b) Each tablet contains
Terbinafine USP 500mg
(as terbinafine hydrochloride)
Excipients    q.s.

For the full list of excipients, see section 6.1.

White, round, flat, 11 mm tablets.


4.1 Therapeutic indications
1.Treatment of Terbinafine tablets sensitive fungal infections such as Tinea corporis, Tinea cruris and Tinea pedis (caused by Dematophytes see Section 5.1) is considered appropriate due to the site, severity or extent of the infection.
2.The treatment of onychomycosis (Terbinafine tablets-sensitive fungal infection of the nails) caused by dermatophytes.

N.B. Orally administered Terbinafine tablets are not effective against Pityriasis versicolor.

The official local guidelines should be borne in mind, for example, national recommendations relating to the correct use and prescription of antimicrobial drugs”.

4.2  Posology and method of administration
250mg once daily.

Renal impairment
Use of Terbinafine tablets has not been adequately studied in patients with renal impairment and is therefore not recommended in this population (see section 4.4 Special warnings and precautions for use and section 5.2 Pharmacokinetic properties).

Liver impairment
Terbinafine tablets are not recommended for patients with chronic or active hepatic disease (see section 4.4 Special warnings and precautions for use).

Skin infections
The likely durations of treatment for Tinea pedis, Tinea corporis and Tinea cruris are 2 – 4 weeks.

For Tinea pedis (interdigital, plantar/moccasin-type): recommended treatment periods may be up to 6 weeks.

Complete disappearance of the symptoms of the infection may not occur until several weeks after mycological cure.

In most patients the duration of successful treatment is 6-12 weeks.

Fingernail onychomycosis: In most cases 6 weeks’ treatment is sufficient in fingernail onychomycosis.

Toenail onychomycosis: In most cases 12 weeks’ treatment is sufficient in toenail onychomycosis although a few patients may require treatment up to 6 months. Poor nail outgrowth during the first weeks of treatment may enable identification of those patients in whom longer therapy is required. Complete resolution of the signs and symptoms of infection may not occur until several weeks after mycological cure and is only seen several months after stopping treatment, which is the time for growth of a healthy nail.

There is no evidence to suggest that elderly patients require different dosages or experience different side effects than younger patients. When prescribing Terbinafine tablets for patients in this age group, the possibility of pre-existing impairment of hepatic or kidney function should be considered (see section 4.4. Special warnings and precautions for use).

Method of administration
Oral use

The duration of treatment is dependent on the indication and the degree of severity of the infection.

4.3 Contraindications
• Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

  • Severe renal impairment
  • Severe hepatic impairment

4.4 Special Warnings and precautions for use
Liver function
Terbinafine tablets are not recommended for patients with chronic or active hepatic disease. Before prescribing Terbinafine tablets, liver function test should be performed. Hepatotoxicity may occur in patients with and without pre-existing hepatic disease therefore periodic monitoring (after 4-6 weeks of treatment) of liver function test is recommended. Terbinafine tablets should be immediately discontinued in case of elevation of liver function test. Very rare cases of serious hepatic failure (some with a fatal outcome, or requiring hepatic transplant) have been reported in patients treated with Terbinafine tablets. In the majority of hepatic failure cases the patients had serious underlying systemic conditions and a causal association with the intake of Terbinafine tablets was uncertain. (see section 4.8 Undesirable effects).

Patients prescribed Terbinafine tablets should be warned to report immediately any signs and symptoms of unexplained persistent nausea, decreased appetite, fatigue, vomiting, right upper abdominal pain, or jaundice, dark urine or pale faeces. Patients with these symptoms should discontinue taking oral Terbinafine tablets and the patient’s hepatic function should be immediately evaluated.

Patients on Terbinafine tablets who develop a high fever or sore throat should be examined concerning possible haematological reactions

Terbinafine tablets should be used with caution in patients with pre-existing psoriasis or lupus erythematosus as very rare cases of lupus erythematosus have been reported.

Terbinafine tablets are a potent inhibitor of the isoenzyme CYP2D6, which should be considered if Terbinafine tablets are combined with medicinal products metabolised by this isoenzyme that are titrated individually (see section 4.5). Dose adjustments may be necessary.

Dermatological effects
Serious skin reactions (e.g. Stevens-Johnson syndrome, toxic epidermal necrolysis) have been very rarely reported in patients taking Terbinafine tablets. If progressive skin rash occurs, Terbinafine tablets treatment should be discontinued.

Haematological effects
Very rare cases of blood disorders (neutropenia, agranulocytosis, thrombocytopenia, pancytopenia) have been reported in patients treated with Terbinafine tablets. Aetiology of any blood disorders that occur in patients treated with Terbinafine tablets should be evaluated and consideration should be given for a possible change in medication regimen, including discontinuation of treatment with Terbinafine tablets.

Renal function
In patients with renal impairment (creatinine clearance less than 50 mL/min or serum creatinine of more than 300 micro mol/L) the use of Terbinafine tablets has not been adequately studied, and therefore, is not recommended (see section 5.2 Pharmacokinetic properties).

4.5 Interaction with other medicinal products and other forms of interaction
The plasma clearance of Terbinafine tablets may be accelerated by drugs which induce metabolism (such as rifampicin) and may be inhibited by drugs which inhibit cytochrome P450 (such as cimetidine). Where co-administration of such drugs is required, it may be necessary to adjust the dose of Terbinafine tablets accordingly.

The following medicinal products may increase the effect or plasma concentration of Terbinafine tablets
Cimetidine decreased the clearance of Terbinafine tablets by 33%.

Fluconazole increased the Cmax and AUC of Terbinafine tablets by 52% and 69% respectively, due to inhibition of both CYP2C9 and CYP3A4 enzymes. Similar increase in exposure may occur when other drugs which inhibit both CYP2C9 and CYP3A4 such as ketoconazole and amiodarone are concomitantly administered with Terbinafine tablets.

The following medicinal products may decrease the effect or plasma concentration of Terbinafine tablets
Rifampicin increased the clearance of Terbinafine tablets by 100%.

Effect of Terbinafine tablets on other medicinal products
According to the results from studies undertaken in vitro and in healthy volunteers, Terbinafine tablets shows negligible potential for inhibiting or enhancing the clearance of most drugs that are metabolised via the cytochrome P450 system (e.g. terfenadine, triazolam, tolbutamide or oral contraceptives) with exception of those metabolised through CYP2D6 (see below).

Terbinafine tablets do not interfere with the clearance of antipyrine or digoxin.

Some cases of irregular menstruation have been reported in patients taking Terbinafine tablets concomitantly with oral contraceptives, although the incidence of these disorders remains within the background incidence of patients taking oral contraceptives alone.

Terbinafine tablets may increase the effect or plasma concentration of the following medicinal products

Terbinafine tablets decreased the clearance of caffeine administered intravenously by 19%.

Compounds predominantly metabolised by CYP2D6
In vitro and in vivo studies have shown that Terbinafine tablets inhibits the CYP2D6-mediated metabolism. This finding may be of clinical relevance for compounds predominantly metabolised by CYP2D6, e.g. certain members of the following drug classes, tricyclic antidepressants (TCAs), beta-blockers, selective serotonine reuptake inhibitors (SSRIs), antiarrhythmics (including class 1A, 1B and 1C) and monoamine oxidase inhibitors (MAO-Is) Type B, especially if they also have a narrow therapeutic window (see 4.4. Special warnings and precautions for use).

Terbinafine tablets decreased the clearance of desipramine by 82%.

Terbinafine tablets may decrease the effect or plasma concentration of the following medicinal products
Terbinafine tablets increased the clearance of ciclosporin by 15%.

4.6 Fertility, Pregnancy and lactation
Foetal toxicity and fertility studies in animals suggest no adverse effects. Since clinical experience in pregnant women is very limited, Terbinafine tablets should not be used during pregnancy unless clinical condition of the woman requires treatment with oral Terbinafine tablets and the potential benefits for the mother outweigh any potential risks for the foetus.

Terbinafine tablets are excreted in breast milk; mothers receiving oral treatment with Terbinafine tablets should therefore not breast-feed.

Foetal toxicity and fertility studies in animals suggest no adverse effects.

4.7 Effects on ability to drive and use machines
No studies on the effects of Terbinafine tablets treatment on the ability to drive and use machines have been performed. Patients who experience dizziness as an undesirable effect should avoid driving vehicles or using machines.

4.8 Undesirable Effects
The following adverse reactions have been observed in the clinical trials or during post marketing experience.

Adverse reactions (Table 1) are ranked under heading of frequency, the most frequent first, using the following convention: very common (≥ 1/10); common (≥ 1/100, < 1/10); uncommon (≥ 1/1,000, < 1/100); rare (≥ 1/10,000, < 1/1,000); very rare (< 1/10,000); not known (cannot be estimated from the available data)

Table 1

Blood and lymphatic system disorders
Very rare:Neutropenia, agranulocytosis, thrombocytopenia, pancytopenia
Not known:Anaemia.
Immune system disorders
Very rare:Anaphylactoid reaction, angioedema, cutaneous and systemic lupus erythematosus
Not known:Anaphylactic reactions, serum sickness-like reaction
Metabolism and nutrition disorders
Very common:Decreased appetite
Psychiatric disorders
Not known:Anxiety, depression*
Nervous system disorders
Uncommon:Hypogeusia**, ageusia**
Very rare:Dizziness, paraesthesia and hypoaesthesia
Not known:Anosmia
Ear and labyrinth disorders
Not known:Hypoacusis, hearing impaired, tinnitus
Vascular disorders
Not known:Vasculitis
Gastrointestinal disorders
Very common:Abdominal distension, dyspepsia, nausea, abdominal pain, diarrhoea.
Not known:Pancreatitis
Hepatobiliary disorders
Rare:Hepatic failure, hepatic enzymes increased
Not known:hepatitis, jaundice, cholestasis
Skin and subcutaneous tissue disorders
Very common:Rash, urticaria
Very rare:Erythema multiforme ,Stevens-Johnson syndrome, toxic epidermal necrolysis, acute generalized exanthematous pustulosis (AGEP)).

Psoriasiform eruptions or exacerbation of psoriasis.


Not known:Photosensitivity reaction, photodermatosis, photosensitivity allergic reaction and polymorphic light eruption
Musculoskeletal and connective tissue disorders
Very common:Arthralgia, myalgia
Not knownRhabdomyolysis
General disorders and administration site conditions
Very rare:Fatigue
Not known:Influenza like illness, pyrexia
Not known:Blood creatinine phosphokinase increased, weight decreased ***

* Anxiety and depressive symptoms secondary to dysgeusia.

** Hypogeusia, including ageusia, which usually recover within several weeks after discontinuation of the drug. Isolated cases of prolonged hypogeusia have been reported.

** *Weight decreased secondary to hypogeusia.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.

4.9 Overdose
Few cases of overdose (up to 5g) have been reported, giving rise to headache, nausea, epigastric pain and dizziness. Recommended treatment for overdose consists of eliminating the active substance, primarily by the administration of activated charcoal, and giving symptomatic supportive therapy if required.


5.1 Pharmacodynamic properties
Pharmacotherapeutic group: Dermatologicals; antifungals for systemic use

Terbinafine tablets is an allylamine which has a broad spectrum of antifungal activity. At low concentrations Terbinafine tablets is fungicidal against dermatophytes, moulds and certain dimorphic fungi. The activity versus yeasts is fungicidal or fungistatic depending on the species.

Terbinafine tablets interfere selectively with fungal sterol biosynthesis at an early stage through inhibition of the enzyme squalene epoxidase. This leads to a deficiency in ergosterol and to an intracellular accumulation of squalene in the fungal cell membrane. Both the deficiency in ergosterol and the accumulation of squalene are responsible for fungal cell death.

When given orally, the active substance concentrates in skin, hair and nails at levels associated with fungicidal activity. Measurable concentrations of the active substance are still evident 15 – 20 days after cessation of treatment.

Terbinafine tablets are used for the treatment of fungal infections of the skin and nails, which is caused by Trichophyton (e.g.T. rubrum, T.mentagrophytes, T. verrucosum, T. violaceum), Microsporum canis and Epidermophyton floccosum. The following table outlines the range of minimum inhibitory concentrations (MIC) against the dermatophytes.

OrganismMIC rang


Trichophyton rubrun0.001 – 0.15
Trichophyton mentagrophytes0.0001 – 0.05
Trichophyton verrucosum0.001 – 0.006
Trichophyton violaceum0.001 – 0.1
Microsporum canis0.0001 – 0.1
Edidermorphyton fluccosum0.001 – 0.05

Terbinafine tablets exhibits poor efficacy against many yeasts of the Candida species.

Terbinafine tablets in contrast to locally administered Terbinafine tablets treatment, has no effect in the treatment of Pityriasis (Tinea) versicolor.

 5.2 Pharmacokinetic properties
A single oral dose of 250mg Terbinafine tablets results in mean peak plasma concentrations of 0.97 mcg/ml within 2 hours after administration. The absorption half-life is 0.8 hours and the distribution half-life is 4.6 hours.

Terbinafine tablets binds strongly to plasma proteins (99%).
Terbinafine tablets rapidly diffuses through the skin and concentrates in the lipophilic stratum corneum. Terbinafine tablets are also secreted in sebum, thus achieving high concentrations in hair follicles, hair and parts of the skin rich in sebaceous glands. There is also evidence that Terbinafine tablets is distributed into the nail plate within a few weeks after commencing therapy.

Terbinafine tablets are rapidly metabolised by the CYP-isoenzymes, mainly by CYP2C9, CYP1A2, CYP3A4, CYP2C8 and CYP2C19. Biotransformation results in metabolites with no antifungal activity, which are excreted predominantly in the urine.

The elimination half-life is 17 hours. There is no evidence of accumulation in the plasma.

No age-dependent changes in pharmacokinetics have been observed but the elimination rate may be reduced in patients with renal or hepatic impairment, resulting in higher blood levels of Terbinafine tablets.

In patients with pre-existing mild to severe hepatic impairment, single dose pharmacokinetic studies have shown that the clearance of Terbinafine tablets can be reduced by 50%.”

The bioavailability of Terbinafine tablets is only slightly affected by food, and therefore a dose adjustment is not necessary.

5.3 Preclinical safety data
The approximate LD50 value of Terbinafine tablets is over 4 g/kg in both mice and rats.

In long-term studies (up to 1 year) in rats and dogs no marked toxic effects were seen in either species up to oral doses of about 100mg/kg a day. At high oral doses, the liver and possibly also the kidneys were identified as potential target organs.

In a two-year oral carcinogenicity study in mice, no neoplastic or other abnormal findings attributable to treatment were made up to doses of 130 (males) and 156 (females) mg/kg a day. In a two-year oral carcinogenicity study in rats, an increased incidence of liver tumours was observed in males at the highest dosage level of 69 mg/kg, at which systemic exposure was similar to clinical exposure. The mechanism of tumour development has not been established. The clinical relevance is unknown. The changes which may be associated with peroxisome proliferation have been shown to be species-specific since they were not seen in the carcinogenicity study in mice, dogs or monkeys.

During high-dose studies in monkeys, refractile irregularities were observed in the retina at the higher doses (non-toxic effect level 50mg/kg). These irregularities were associated with the presence of a Terbinafine tablets metabolite in ocular tissue and disappeared after discontinuation of the active substance. They were not associated with histological changes.

A standard battery of in vitro and in vivo genotoxicity tests revealed no evidence of mutagenic or clastogenic potential.

No undesirable effects on fertility or other reproduction parameters were observed in studies in rats or rabbits.


6.1 List of excipients
Magnesium stearate
Silica, colloidal anhydrous
Croscarmellose sodium
Microcrystalline cellulose

6.2 Incompatibilities
Not applicable.

6.3  Shelf life
Al/PVC-PVdC blister
3 years
HDPE tablet container with LDPE cap
18 months

6.4 Special precautions for storage
This medicinal product does not require any special storage conditions

6.5 Nature and contents of container
Al/PVC-PVdC blister and HDPE tablet container with LDPE cap
Pack Sizes:
HDPE bottles: 14, 28, 500 tablets
Blisters: 7, 14, 20, 28, 30, 42, 50, 60, 84, 90, 98, 100, 50 x 1 (unit dose) tablets
*Not all container types or pack sizes may be marketed.

6.6 Special precautions for disposal and other handling
No special requirements

7. Manufactured In India By:
Mumbai, India
Unit No. 214.Old Bake House,
Maharashtra chambers of  Commerce Lane,
Fort, Mumbai – 400001
at:Gujarat, INDIA.
Customer Service and Product Inquiries:
1-800-TRY-FIRST (1-800-222-434 & 1-800-222-825)
Monday through Saturday 9:00 a.m. to 7:00 p.m. EST
E-mail: tajgroup@tajpharma.com

Terbinafine Tablets USP 500mg Taj Pharma

Package leaflet: Information for the patient

a) Terbinafine Tablets USP 250mg Taj Pharma
b) Terbinafine Tablets USP 500mg Taj Pharma

Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
– Keep this leaflet. You may need to read it again.
 – If you have any further questions, ask your doctor or pharmacist.
– This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
– If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor.

What is in this leaflet
1. What  Terbinafine is and what it is used for
2. Before you are given Terbinafine
3. How you will be given  Terbinafine
4. Possible side effects
5. How Terbinafine is stored
6. Further Information

1. What Terbinafine is and what it is used for
Terbinafine is an antifungal medicine used to treat fungal skin and nail infections.

2. Before you are given Terbinafine
DO NOT take Terbinafine Tablets

  • if you are allergicto terbinafine, or any of the other ingredients of this medicine listed in section 6
  • if you have or have had any liver problems
  • if you are breast-feeding.

Warnings and precautions
Talk to your doctor or pharmacist before taking Terbinafine Tablets. If the answer to any of these questions is YES, Terbinafine Tablets might not be the right medicine for you.

  • Are you pregnantor trying to become pregnant?
  • Do you have any problems with your kidneysor liver?
  • Do you have psoriasis?
  • Do you have systemic lupus erythematosus (SLE)?
  • Do you have a rashdue to a high level of a specific type of white blood cells?

Children and adolescents

Children should not normally be given Terbinafine Tablets.

Other medicines and Terbinafine Tablets
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.

Some medicines can interfere with your treatment. Tell your doctor if you are taking any of the following:

  • rifampicin,an antibiotic used to treat fever and infections
  • cimetidine,used to treat stomach ulcers or to reduce the amount of acid in your stomach
  • oral contraceptives.If your periods become irregular or if you have any breakthrough bleeding, then ask your doctor if other contraceptives are needed whilst taking this medicine
  • antidepressants,g. imipramine, nortriptyline, amitriptyline, fluoxetine, paroxetine
  • beta-blockersor anti-arrhythmics for heart problems
  • warfarin,a medicine used to thin your blood
  • medicines used to treat heart problems (e.g. propafenone, amiodarone)
  • ciclosporin,a medicine used to control your body’s immune system in order to prevent rejection of transplanted organs
  • medicines used to treat fungal infections (e.g. fluconazole, ketoconazole)
  • medicines used to treat cough (e.g. dextromethorphan)
  • caffeine.

You should have blood tests before and during treatment with Terbinafine Tablets to monitor your liver function.

Driving and using machines
Some people have reported feeling dizzy or giddy while they are taking Terbinafine Tablets. If you feel like this, you should not drive or operate machinery.

3. How you will be given Terbinafine
Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.
The usual dose for adults, including the elderly is 250 mg once a day.

  • For skin infections continue taking the tablets for 2 to 6 weeks.
  • For nail infections treatment usually lasts for between 6 weeks and 3 months, although some patients with toenail infections may need to be treated for 6 months or longer.
  • If your kidneys are not working very well, your doctor may reduce the dose of Terbinafine Tablets you take.
  • Swallow the tablets/tablet halves whole with a glass of water.

The score line is only to facilitate breaking for ease of swallowing and not to divide into equal doses.

If you take more Terbinafine Tablets than you should
All tablets can be risky if you take too many. If you take too many Terbinafine Tablets at once, tell your doctor or hospital casualty department as soon as possible Take your medicine pack with you so that people can see what you have taken.

If you forget to take Terbinafine Tablets
Take one as soon as you remember unless it is nearly time to take the next one. Do not take two tablets to make up for the forgotten one. If you are unsure, ask your doctor or pharmacist.

If you have any further questions on the use of this medicine ask your doctor or pharmacist.

4. Possible Side Effects
Like all medicines, this medicine can cause side effects, although not everybody gets them.

Any side effects are usually mild or moderate and don’t last for too long.

Some side effects can be serious
Stop taking the tablets and tell your doctor immediately if you notice any of the following rare symptoms:

  • yellowing of your skin or eyes. Unusually dark urine or pale faeces, unexplained persistent nausea, stomach problems, loss of appetite or unusual tiredness or weakness (this may indicate liver problems), increase in liver enzymes which may be noted on a blood test result
  • severe skin reactions including rash, light sensitivity, blistering or wheals
  • weakness, unusual bleeding, bruising, abnormal pale skin, unusual tiredness, or weakness or breathlessness on exertion or frequent infections (this may be a sign of blood disorders)
  • difficulty breathing, dizziness, swelling mainly of the face and throat, flushing, crampy abdominal pain, stiffness, rash, fever or swollen/enlarged lymph nodes (possible signs of severe allergic reactions)
  • symptoms such as rash, fever, itching, tiredness or if you notice appearance of purplish spots under the skin surface (signs of blood vessel inflammation)
  • severe upper stomach pain which spreads to the back (possible signs of pancreas inflammation)
  • unexplained muscle weakness or pain, or dark (red-brown) urine (possible signs of muscle breakdown)

The most common side effects are:

  • headache
  • stomach problems such as loss of appetite, ache, indigestion, feeling bloated or sick
  • diarrhoea
  • itching, rash or swelling
  • pains in the muscles and joints

The side effects listed below have also been reported.

Uncommon (may affect up to 1 in 100 people)

  • taste loss and taste disturbance. This usually disappears within several weeks after you stop taking this medicine. However, a very small number of people (less than 1 in 10,000), have reported that the taste disturbance lasts for some time and as a result they go off their food and lose weight. There have also been reports of some people experiencing anxiety or symptoms of depression as a result of these taste disturbances.

Rare (may affect up to 1 in 1,000 people)

  • feeling unwell, dizzy
  • numbness or tingling.

Very rare (may affect up to 1 in 10,000 people)

  • feeling tired, decrease in the number of some blood cells. You may notice that you seem to bleed or bruise more easily than normal, or you may catch infections easily and these might be more severe than usual
  • psoriasis like skin eruptions, or worsening of any psoriasis including a rash or eruption of small pus containing blisters
  • vertigo
  • hair loss
  • onset or worsening of a condition called lupus (a long-term illness with symptoms including skin rash and pain in the muscles and joints).

Frequency not known (frequency cannot be estimated from the available data)

  • Signs of blood disorders: weakness, unusual bleeding, bruising or frequent infections.
  • Disorders of sense of smell which may be permanent, impaired hearing, hissing and/or ringing in the ears, flu like symptoms, increase in blood of a muscle enzyme called creatine phosphokinase (may be found on a blood test), reduced or blurred vision.

Reporting of side effects
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet.. By reporting side effects you can help provide more information on the safety of this medicine.

5. How Terbinafine is stored
Keep in the original packaging. Keep this medicine out of the sight and reach of children.
Do not store above 25˚C.
Do not use this medicine after the expiry date which is stated on the blister, carton or label. The expiry date refers to the last day of that month.
Do not use this medicine if you notice signs of deterioration such as discolouration or crumbling.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist to throw away medicines you no longer use. These measures will help to protect the environment.

6. Further information

What Terbinafine contains
The active substance is terbinafine.
a) Each tablet contains
Terbinafine USP 250mg
(as terbinafine hydrochloride)
Excipients     q.s.

b) Each tablet contains
Terbinafine USP 500mg
(as terbinafine hydrochloride)
Excipients       q.s.

Terbinafine Tablets also contain the inactive ingredients magnesium stearate (E470b), colloidal anhydrous silica, hypromellose (E464), microcrystalline cellulose (E460) and croscarmellose sodium (E468).

What Terbinafine looks like and contents of the pack
Terbinafine Tablets are round white to off-white flat tablets with a break line on one side..

The tablets are available in: blister packs of 14, or 28 tablets or bottles of 60, 100 or 500 tablets.
Not all pack sizes may be marketed.

7. Manufactured In India By:
Mumbai, India
Unit No. 214.Old Bake House,
Maharashtra chambers of  Commerce Lane,
Fort, Mumbai – 400001
at:Gujarat, INDIA.
Customer Service and Product Inquiries:
1-800-TRY-FIRST (1-800-222-434 & 1-800-222-825)
Monday through Saturday 9:00 a.m. to 7:00 p.m. EST
E-mail: tajgroup@tajpharma.com